Technology
Applications
Resources
Support
Company
Contact
EN
EN
- Global
CN
- 中国
menu
Close
Home
Technology
Applications
Pharmacogenetics
Liquid Biopsy
Mutation Profiling
Hereditary Genetics
Methylation
Sample Integrity
Specimen Validity
Services
Assays by Agena
Certified Service Providers
Resources
Product Literature
Publication Library
Support
Service Plans
Distributors
Certified Service Providers
Company
Careers
Press
Contact
Customer Support Portal
Home
Technology
Applications
Pharmacogenetics
Mutation Profiling
Liquid Biopsy
Hereditary Genetics
Methylation
Sample Integrity
Specimen Validity
Services
Assays by Agena
Certified Service Providers
Resources
Product Literature
Publication Library
Support
Service Plans
Distributors
Certified Service Providers
Company
Careers
Press
Contact
Customer Support Portal
Phone: (858) 882-2800
Home
/
Resources
/
Publication Library
Search Results for: Liquid Biopsy
Search All publications
How recent?
Search
Recent Developments in Mutation Enrichment and Detection Technologies
Exhaled Breath Condensate (EBC) analysis of circulating tumour DNA (ctDNA) using a lung cancer specific UltraSEEK oncogene panel
Circulating tumor DNA in cancer diagnosis, monitoring, and prognosis
Application of liquid biopsy-based targeted capture sequencing analysis to improve the precision treatment of non-small cell lung cancer by tyrosine kinase inhibitors
Ultrasensitive analysis of genetic instability related to chemical exposure
The identification of circulating tumour DNA using MassARRAY technology in non-small-cell lung cancer (NSCLC)
Cross-platform comparison of next-generation sequencing and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for detecting KRAS/NRAS/BRAF/PIK3CA mutations in cfDNA from metastatic colorectal cancer patients
A pan-Canadian validation study for the detection of EGFR T790M mutation using circulating tumour DNA (ctDNA) from peripheral blood
Emerging Role of Circulating Tumour DNA in Treatment Response Prognosis in Colon Cancer
Multiplex technologies for the assessment of minimal residual disease and low-level mutation detection in leukaemia: mass spectrometry versus next-generation sequencing
«
1
2
3
4
5
...
»